KRAS and ovarian carcinoma: On the other hand, given that RAS mutant tumors are usually resistant to PARP inhibitors and other anticancer drugs, the inhibition of MEK and ERK can reverse PARP inhibitor resistance in KRAS mutant tumors, including ovarian cancer.